# polydeoxyribonucleotide (PDRN) Topic radar · 566 documents · 2021-01-01–2026-10-16 · updated 2026-10-28 Canonical: https://slate.greyb.com/radar/polydeoxyribonucleotide-pdrn/innovations ## In one minute ### The receptor mechanism is established, and blocking the receptor removes the effect PDRN is a mixture of short DNA fragments, conventionally purified from salmon sperm or testes and usually described as 50 to 1,500 kilodaltons in size [1]. It works through two routes at once. It binds the adenosine A2A receptor, the receptor that endogenous adenosine uses to resolve inflammation, and it supplies nucleotides to the salvage pathway cells use to rebuild DNA. The strongest evidence on this molecule is that the effect disappears when the receptor is blocked. An A2A antagonist abolished PDRN's benefit in two rat models of colitis [2]. A different antagonist did the same in inflamed gingival and oral mucosal cells [3]. A third reversed PDRN's effect on psoriasis-like skin in mice [4]. Three labs, three tissues, one result. One detail matters for everything downstream. The intracellular signal splits by cell type. In fibroblasts PDRN raises ERK phosphorylation and collagen accumulation. In keratinocytes it lowers ERK phosphorylation and reduces inflammatory cytokine output [5]. The same molecule has to reach two cell populations that need opposite things from it. 1. [10.3389/fphar.2017.00224](https://doi.org/10.3389/fphar.2017.00224) 2. [10.3389/fphar.2016.00273](https://doi.org/10.3389/fphar.2016.00273) 3. [10.1016/j.biopha.2021.111538](https://doi.org/10.1016/j.biopha.2021.111538) 4. [10.3390/ijms21041215](https://doi.org/10.3390/ijms21041215) 5. [10.3892/mmr.2023.13035](https://doi.org/10.3892/mmr.2023.13035) ### The commercial record belongs to one country and one company Korea's polynucleotide injectables market was USD 88.0 million in 2025 and is projected to reach USD 321.8 million by 2033, about 16.8 percent a year, with Korea holding 35.9 percent of the global total. PharmaResearch reported first-quarter 2026 revenue of 146.1 billion won, up 25 percent, with operating profit up 28 percent to 57.3 billion won and exports at 40 percent of revenue. Second-quarter revenue reached 178.7 billion won with cosmetics exports up 124 percent, and the company runs near a 40 percent operating margin. ### The centre of gravity has moved upstream Across the six areas covered here, patent publications are distributed very differently from the commercial market. Sourcing and extraction, the work of getting intact DNA out of a tissue and cutting it to a length, holds 197 publications. Delivery and formulation holds 147, topical formulations 125. The injectable area, where the revenue, the clinical evidence and the regulatory scrutiny all sit, holds 53. ### A molecule of that size does not cross skin on its own Two physical facts drive the formulation work across every area here. PDRN is large and heavily negatively charged, so intact skin is a poor route. And it is DNA, so nucleases in the skin and in a water-based emulsion dismantle it before it acts. ### The home premium is already being competed away Domestic medical-device growth fell from 93.5 percent to 6.2 percent. The company attributes it to a 2025 medical-tourism base, but competitor Lituo is growing faster and extracellular-matrix products are projected to move from 3.9 to 17.3 percent penetration against Rejuran. ### China is solving manufacturing, Korea is solving the label One hundred and sixty-nine Chinese patent publications in 2026 against 83 Korean, from 14 and 11 in 2021. Chinese offices account for 90 of the 197 sourcing documents. ### A carrier buys a measured gain of about twenty percent The published measurement is short enough to quote in full. A PDRN nanoliposome came out at 125 nanometres with 81.3 percent encapsulation, and over 24 hours its cumulative skin permeation was 1.22 times that of free PDRN with 1.40 times the skin retention. ### China registered tens of thousands of cosmetics and has approved no injectable Registration is the cheap step: more than 17,000 cosmetic products containing sodium DNA, the ingredient name PDRN is registered under, were registered in China in the first half of 2025. Around 4,000 brands are in the category, and combined sales on Tmall, JD.com and Douyin rose from 1.5 million yuan in 2022 to 408 million in 2025, with 223 million in the first four months of 2026. Rejuran Cosmetics entered Sephora China in December 2025. ## Overview PDRN works by binding the adenosine A2A receptor, and blocking that receptor removes the effect in rat colitis, inflamed oral mucosa and psoriasis-like mouse skin. The biology is not the constraint. ## Research ### The DNA is doing work other than being delivered Across the delivery and injectable areas the molecule has moved out of the cargo position. ### No one can state what pharmaceutical-grade PDRN is, and fragment size changes the result Two filings build a viscoelastic gel for the same purpose from DNA of very different lengths. Mastelli specifies 50 to 500 base pairs, preferably 100 to 370. Hyundai Bioland specifies 1,600 to 2,500 kilodaltons. A base pair weighs roughly 650 daltons, so the two preferred ranges sit about tenfold apart. ### The activity does not require the fish The A2A action belongs to the nucleotide mixture, and the record now shows it in material that never touched a salmon. Ginseng adventitious-root PDRN acted as an A2A agonist and drove keratinocyte and fibroblast proliferation with filaggrin and fibronectin expression. A peony-derived low molecular weight fraction reduced transepidermal water loss after two weeks in a damaged-skin model of ten people and improved periorbital elasticity at four. Paeonia callus polynucleotides raised collagen I through the same cAMP/PKA/CREB route, with the authors reporting comparability to the salmon material. A red algal extract suppressed nitric oxide and p38/ERK phosphorylation in macrophages. ### The clinical proof sits in the joint, and the skin evidence is borrowed The one place with randomized human evidence is intra-articular use. A pooled analysis of five trials found PDRN relieved knee pain better than hyaluronic acid at one and two months, with no difference at four months and no difference in function. A review of twelve studies found better pain and function at two and four months while flagging limited statistical power and possible publication bias. A 100-patient trial found a polynucleotide plus hyaluronic acid combination beat hyaluronic acid alone on knee function and pain. ## Strategy ### One company is building a chain while the rest hold single points Bloomage is the only organisation publishing in sourcing, topical, injectables and acne at once: 13, 6, 5 and 2 publications respectively. Its sourcing work runs from sequence design to expression: specific-sequence PDRN with defined GC content, self-assembling nucleic acid tetrahedra built from screened PDRN sequences, a PDRN salt at above 95 percent content and under 1 percent protein. In August 2026 it commissioned a dedicated PDRN and polynucleotide plant in Weihai. ### The market leader publishes around its product PharmaResearch appears seven times in the whole record, and none of those publications claims an injectable filler composition. The subjects are retinol combinations for topical use, a cationic-additive hair growth composition and its predecessor, a permeability-enhanced wrinkle composition, a chitosan and DNA fragment composition for atopic dermatitis, and an ischaemic brain disease composition with Kyung Hee University. ### The filings are domestic, so they protect domestic markets Nine international applications in 2026, four US publications, four Japanese, one Taiwanese. Nothing at the European office since a single publication in 2023, after three in 2021. Nearly everything else sits in the Chinese and Korean offices. ### The quality specification is where almost nobody is filing Of 106 sourcing publications in 2026, very few claim a measurable specification. Among those that do, one states a content above 95 percent with protein under 1 percent and bounded viscosity loss after sterilisation, another a polydispersity index of 1.1 to 1.3 with a 40 to 200 kDa range, and a third a defined fragment distribution of 50 to 500 base pairs. ## Areas - Delivery Systems & Formulation Platforms · 147 documents - Topical Anti-Aging & Skin Repair · 125 documents - Injectable Aesthetics & Regenerative Medicine · 53 documents - PDRN Sourcing & Extraction · 197 documents - Hair Growth & Scalp Care · 22 documents - Acne & Specialized Dermatology · 13 documents